Modeling the impact of Malakit intervention: one more step towards malaria elimination in the Guiana Shield?

- 1 Yann Lambert^{1*}, Raphaëlle Métras², Alice Sanna¹, Muriel Galindo¹, Helene Hiwat³, Paola
- 2 Marchesini⁴, Stephen Vreden⁵, Martha Cecilia Suárez-Mutis⁶, Oscar Mesones Lapouble⁷,
- 3 Antoine Adenis¹, Mathieu Nacher¹, Pierre-Yves Boëlle², Chiara Poletto^{8§}, Maylis Douine^{1§}
- 4 ¹ Centre d'Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne
- 5 Andrée Rosemon, Cayenne, French Guiana
- ² Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP),
 Paris, France
- ³ Malaria program, Ministry of Health of Suriname, Paramaribo, Suriname
- 9 ⁴ Malaria Technical Group, Vector Transmissible and Zoonotic Diseases Coordination, Ministry of
- 10 Health, Brasilia, Brazil
- ⁵ Foundation for Scientific Research Suriname, Paramaribo, Suriname
- ⁶ Laboratory of Parasitic Diseases, Institute Oswaldo Cruz/Fiocruz, Rio de Janeiro, Brazil
- ¹³ ⁷ Pan American Health Organization / World Health Organization (PAHO/WHO) Country Office in
- 14 Suriname
- ⁸ Department of Molecular Medicine, University of Padova, Padova, Italy
- 16
- 17 * Correspondence: Yann Lambert, <u>y.m.lambert@free.fr</u>
- 18 [§] Both authors contributed equally to this work.
- 19 Keywords: malaria elimination; hard-to-reach population; gold mining; French Guiana; impact
- 20 evaluation; mathematical modeling
- 21
- 22

23 Abstract

24 *Background:* Malaria elimination in mobile and hard-to-reach populations calls for new, tailored 25 interventions. In the Guiana Shield countries, the malaria burden is high in the population working in

26 illegal gold mining. Between April 2018 and March 2020, we implemented Malakit, a new intervention

27 targeting gold miners, and relying on the distribution of kits for self-diagnosis and self-treatment. In

this study, we evaluate the impact of Malakit on malaria transmission.

29 Methods: We fitted a mathematical model of malaria transmission to surveillance data from Brazil and

30 Suriname, and to prevalence data from cross-sectional surveys, to estimate the change in treatment

31 coverage and reproduction number between the pre-intervention (2014-2018) and intervention (2018-

32 2020) periods.

33 Results: Model results show that treatment coverage of symptomatic all-species malaria infections

34 increased from 26.4% (95% CrI 22.8, 30.3) prior intervention to 55.1% (95% CrI 49.9, 60.8) during the

intervention, leading to a decrease of the reproduction number from 1.19 to 0.86. We estimate that on

36 average 6943 all-species malaria infections were averted during the intervention, corresponding to a

37 48.7% reduction in incidence and 43.9% reduction in total infection prevalence.

38 *Discussion:* Malakit had a significant impact on malaria transmission by improving the access to 39 treatment of the population working in illegal gold mining in French Guiana. Building on the regional 40 efforts of the past twenty years, Malakit contributed to another step towards malaria elimination in the

- 41 Guiana Shield.
- 42

44 **1** Introduction

45 Addressing malaria in mobile, migrant and hard-to-reach populations remains a challenge for countries on the way to malaria elimination, and call for tailored and innovative strategies to improve access to 46 47 diagnosis, treatment and vector protection (1–3). In the Amazon region, the communities involved in 48 gold mining are a typical example of such populations with residual malaria (4). In French Guiana, the 49 population working in illegal gold mining sites has been identified as the main reservoir of malaria in the region, predominantly infected with *Plasmodium falciparum*, and producing the majority of cases 50 exported to the neighboring countries (5.6). Their lack of access to proper diagnosis and treatment 51 52 translates into self-medication with under-the-counter antimalarials, a major risk for the emergence of

- 53 artemisinin resistance.
- 54 To address this local and regional challenge, French Guiana, Suriname and Brazil jointly implemented
- a new intervention named Malakit. This intervention relied on the distribution of kits for self-diagnosis
- and self-treatment, associated to a training session, to gold miners going to work in French Guiana
- from the borders with Brazil and Suriname (7). Between April 2018 and March 2020, health facilitators
- trained 3733 participants and distributed 4766 kits, reaching about one third of the target population.
- 59 The pre- post- evaluation of the intervention showed an improvement of knowledge and practices of
- 60 gold miners towards malaria care and a drop in Polymerase Chain Reaction (PCR) prevalence of
- 61 *Plasmodium* spp.. National malaria surveillance systems recorded a decrease of the incidence of 62 symptomatic cases imported from French Guiana concomitant with Malakit implementation. A
- 63 preliminary interrupted time series analysis (ITSA) estimated at 43% the reduction of cases notified
- 64 during the implementation of Malakit (8); still, ITSA does not make explicit assumptions on the
- 65 mechanisms involved in malaria transmission thus limiting the investigation of the effect of the Malakit
- 66 intervention.

Here we developed a mechanistic mathematical model explicitly accounting for malaria transmission, case detection and Malakit uptake during the intervention period. We employed a Bayesian approach to fit the model to surveillance and cross-sectional surveys' data to estimate changes in treatment coverage and reproductive ratio. Then, by comparing the model outputs from the pre-intervention period (2014-2018) with the intervention period (2018-2020) we quantified the impact of Malakit on malaria incidence and prevalence, considering *P. falciparum* (*Pf*), *P. vivax* (*Pv*) and both species combined.

- 74
- 75
- 76
- 77
- 78


79 2 Materials and Methods

80 2.1 Population and settings

French Guiana is a French overseas territory located in South America, sharing borders with Brazil in the East, and Suriname in the West. Ninety percent of its land (85 000 km²) is covered by rainforest with a soil rich in gold – a geological characteristic shared by the countries of Guiana Shield. This gold is the reason for the continuous presence of an estimated population of 10 000 men and women on 500 to 700 illegal gold mining sites (9). The majority of gold miners are born in Brazil (>95%), 75% are men, with a median age of 38 (IQR: 31, 47), and less than half have a secondary level of education (5,8).

88 2.2 Intervention

89 The Malakit intervention has been described in several articles (7,10,11). Coordinated by Cayenne 90 Hospital, Malakit was implemented between April 2018 and March 2020 at five sites mainly located 91 at the borders of French Guiana with Brazil and Suriname (Figure 1). These sites were selected because 92 of their strategic importance as entry points for gold miners going to French Guiana. The core 93 intervention relied on the distribution of free kits for the self-diagnosis and self-treatment of malaria to 94 gold miners by health facilitators. One kit contained three non-species-specific rapid diagnostic tests 95 (RDT) for malaria, a full course of artemisinin combined therapy (ACT) (artemether - lumefantrine) and a single dose of primaquine (S-PQ). Before distributing a kit, health facilitators trained the 96 participants to use the kit by making them perform an RDT themselves and explaining how to take the 97 98 medication. Long lasting impregnated nets (LLINs) were also distributed to participants during the full 99 course of the intervention in Suriname, and during the last six months of the intervention in Brazil.



100

101 Figure 1: Map showing the location of Malakit distribution sites and pre/post intervention cross-

102 sectional surveys enrolment sites at the borders of French Guiana with Brazil and Suriname

103

104 2.3 Malaria prevalence and surveillance data

105 We conducted cross-sectional surveys before and after the intervention to assess knowledge and self-106 reported practices about malaria treatment and diagnosis, and to estimate the prevalence of *Plasmodium* carriage by PCR in the population (5,8). Monthly notification data of malaria cases imported from 107 108 French Guiana to Brazil and Suriname were obtained from national surveillance systems of the Brazilian and Surinamese malaria programs. From these surveillance data, we used only cases imported 109 110 from French Guiana, and explicitly recorded as originating from gold mining. We chose not to use surveillance data from French Guiana because they do not allow consistently to identify cases 111 112 specifically originating from mining areas.


113 2.4 Malaria transmission model

114 We developed a deterministic Susceptible-Infectious-Susceptible (SIS) compartmental model to

simulate the transmission of malaria in a single population encompassing all individuals living in illegal

- 116 gold mining sites in French Guiana. We used a human-to-human transmission rate which accounted
- for the vector population dynamics (12-14) with a seasonal forcing defined as an exponential effect of

individuals with a detectable parasite density in PCR and was distributed into four model compartments: asymptomatic (IA), symptomatic but not (or incompletely) treated (IS) and symptomatic treated either by the health system (IT) or with the use of a malakit (IM). Susceptible individuals (S) were free from disease. We assumed that cases notified to the malaria surveillance systems (D) was a fraction of the infected individuals receiving treatment from health systems (IT) (Figure 2).



125

126	Figure 2: Compartments used in the malaria transmission model and sources of data used for
127	calibration. Susceptible individuals (S) may get infected with malaria without symptoms (IA), or
128	develop symptoms without appropriate treatment (IS), get treatment from the health system (IT)
129	or from using a malakit (IM, during intervention). A fraction of the cases treated by the health
130	system are notified to malaria surveillance (D).

131 Our model relied on the following assumptions: (i) the population size is constant, (ii) the mixing of 132 individuals is homogeneous, (iii) the force of infection depends on meteorological conditions, with 133 temperature chosen as explanatory variable; (iv) infected individuals have a constant probability ε of 134 being symptomatic; (v) the rate of transmission from asymptomatic individuals is lower than from 135 symptomatic individuals, with a constant ratio k < 1; (vi) only symptomatic individuals are treated with probabilities φ_0 and φ_1 , prior and during Malakit implementation respectively; (vii) prior to 136 137 Malakit implementation all individuals are treated by the health systems (φ_0), while during the 138 intervention period a proportion *m* of symptomatic individuals is treated with Malakit and a proportion $\varphi_1 - m$ is treated by health systems; (viii) the proportion of individuals who seek care from the health 139 remains the same during the intervention period ($\phi_0 = \phi_1 - m$); (ix) treatment shortens the infection 140

141 duration; (x) treatment does not affect the transmission rate; (xi) without treatment, the duration of

142 infection is the same for asymptomatic and symptomatic individuals; (xii) individuals who seek

143 treatment from the health system are notified to malaria surveillance in Brazil and Suriname with a

144 constant reporting fraction ρ ; and (xiii) individuals using Malakit for treatment are not reported to

- 145 malaria surveillance.
- 146 Model equations and parameters definitions are presented in the supplementary methods.

147 **2.5 Parameters estimation**

- We fitted our model to prevalence and surveillance data for 1) all species, 2) *Pf*, and 3) *Pv*. We estimated the posterior distribution of six parameters: probability of treatment before intervention (φ_0),
- 150 probability of treatment during intervention (φ_1), probability of symptomatic infection (ε),
- transmission rate at average maximum daily temperature (β_0), temperature-associated amplitude of
- 152 transmission rate (α) and temperature-associated lag of the transmission rate (lag). We fixed the values
- of the reporting fraction (ρ =0.69), the duration of infection with treatment (T_T =7 days), the initial
- number of infected individuals (I_0 , specie-specific), the duration of infection without treatment (T_{NT} ,
- specie-specific), and the ratio of asymptomatic vs. symptomatic transmission rates (*k*, specie-specific). Reporting fraction was ρ =0.69, while the duration of infection with treatment was T_T =7 days. Values
- 157 of I_0 , T_{NT} , and k for Pf, Pv or both species combined are reported in the supplementary materials.
- The log-likelihood associated to parameters estimates was calculated by fitting monthly simulated notifications to surveillance data assuming Poisson distribution, and simulated prevalence to 2015,
- 160 2018 and 2019 data assuming binomial distribution.

We used R (v4.2.0) and RStudio (v2022.02.3) to run three Markov chains of 100 000 iterations using different seed values, for each model fit. We used the Robust Adaptative Metropolis algorithm developed by Vihola (15) and implemented in R by Helske (16). We discarded the first 20 000 iterations of the burn-in periods and thinned at a ratio of 1:10 to eliminate auto-correlation and combined the three chains. We checked for convergence to the same stationary distribution both visually and using Gelman statistics from coda R package (17) (supplementary Table 10).

167 At each iteration of the Markov chains, we computed the probability of using a malakit, m, from fitted 168 values of φ_0 and φ_1 ; the mean infection duration (T) and the reproduction number (R), before and 169 during intervention, and derived the mean and 95%CrI from the resulting distributions. We performed 170 a sensitivity analysis of the variation of the parameters' posterior distribution for different values of I_0 171 and T_{NT} .

172 **2.6 Estimation of the impact of Malakit**

To assess the impact of the Malakit intervention on malaria incidence and prevalence, we ran simulations parameterized from a sample of 1000 draws from the parameter posterior distributions.

175 For each one of the 1000 draws of parameter values, we compared the model simulation to a matching

176 counterfactual (without intervention) with φ_1 set to the pre-intervention value φ_0 . We then calculated

177 the difference between the mean prevalence, the mean annual incidence rate and the cumulated

incidence estimated by each pair of simulations, and derived the mean and 95% CrI from the resulting

179 distributions.

180 **2.7 Ethics and regulation**

181 Ethics approvals the were obtained from countries where the Malakit study was implemented (8). All

182 data from the Malakit project (intervention and cross-sectional surveys) were obtained anonymously

183 after a written consent from participants. The analysis of all data complies with the General Data

- 184 Protection Regulation (European Union Regulation 2016/679).
- 185

186 **3 Results**

187 **3.1 Impact on all-species malaria transmission**

188 Table 1 presents the values of estimated parameters. Over the full period 2014-2020 we estimate that 189 47.1% (95%CrI 38.8, 56.6) of new all-species malaria infections were symptomatic. Our model 190 estimates the treatment coverage of symptomatic infections at 26.4% (95%CrI 22.8, 30.3) prior to the 191 implementation of the Malakit intervention and 55.1% (95%CrI 49.9, 60.8) during the intervention, 192 corresponding to a two-fold increase. According to our assumptions, this improvement of treatment 193 coverage corresponds to a probability of 28.7% (95%CrI 25.0, 32.6) of using Malakit to treat a new 194 symptomatic infection (NSI). This evolution translates into a 12-day decrease of the mean duration of 195 infection (from 45 to 33 days, asymptomatic and symptomatic infections combined) and thus to a 196 reduction of all-species malaria transmission, with a reproduction number (at average temperature) 197 estimated at 1.19 (95%CrI 1.16, 1.22) prior intervention and 0.86 (95%CrI 0.83, 0.90) during the 198 intervention.

In the sensitivity analysis conducted for different values of T_{NT} and I_0 , most parameters showed little variation aside from ε . Importantly, computed values of reproductive number, prior and during intervention, showed little or no variation. The mean estimates of φ_0 and φ_1 increased from 0.22 to 0.28, and from 0.50 to 0.57, respectively, however with consistently overlapping 95%CrIs (supplementary Table 7).

- 204
- 205
- 206
- 207

Table 1: Posterior distributions (mean and 95% credible interval CrI) for all-species malaria transmission model.


Parameter	Pre-intervention, 2014-2018 (95%CrI)	Intervention, 2018-2020 (95%CrI)
φ: Treatment coverage	26.4% (22.8, 30.3)	55.1% (49.9, 60.8)
m: Probability of using a kit in case of symptoms*	-	28.7% (25.0, 32.6)
Probability of symptoms 47.1% (38.8, 56.6)		3.8, 56.6)
β_0 : Transmission rate at average temperature (day ⁻¹)	0.027 (0.023, 0.031)	
α : Seasonal amplitude of transmission rate (°C ⁻¹)	0.097 (0.078, 0.115)	
lag: Temperature lag of transmission rate (days)	83 (73, 94)	
T: Mean infection duration (all infections) (days)*	45 (39, 52)	33 (28, 38)
R: Mean reproduction number (all infections)*	1.19 (1.16, 1.22)	0.86 (0.83, 0.90)

* Calculated from other parameters (see supplementary methods)

210

211 Figure 3 shows the model fit to surveillance and prevalence data for all-species cases of malaria. The 212 mean annual incidence rate dropped from 366 NSI/1000/year (95% CrI 304, 428) to 169 (95% CrI 131, 213 207), prior vs. during the intervention. In parallel, the mean notification rate is estimated to have 214 decreased from 66 NSI/1000/year (95% CrI 50, 82) prior intervention, to 31 (95% CrI 20, 42) during 215 intervention, representing a reporting fraction of 18.2%. Without intervention, the counterfactual 216 scenario predicts that the mean incidence rate could reach 330 NSI/1000/year (95%CrI 262, 398). 217 Therefore, we estimate that Malakit contributed to a 48.7% reduction of the all-species malaria 218 incidence (intervention vs. counterfactual) and accounted for 81.5% of the total decrease of incidence 219 since its implementation.

The total prevalence (symptomatic and asymptomatic infections) is estimated to have decreased on average from 19.6% (95%CrI 17.8, 21.4) before intervention to 9.6% (95%CrI 8.5, 10.7) during intervention. Without intervention, counterfactual simulations predict that the prevalence could decrease to 17.1%. We thus estimate that Malakit led to a reduction of 43.9% of all-species malaria prevalence (supplementary Table 6).





227 Figure 3: Monthly incidence of all-species reported cases of malaria (black dots), model-fitted 228 simulations (blue solid line) and counterfactual estimates (dashed grey line). Annual all-species 229 prevalence measured in PCR surveys (orange dots) and model-fitted estimates of prevalence (red 230 dots). Maximum daily temperature (monthly average) is shown in green dashed line. The period of implementation of Malakit is shown in yellow. Vertical lines represent 95%CrI. For model-231 232 fitted and counterfactual incidence (respectively blue and grey), the dark envelopes show the 233 uncertainty (95%CrI) associated to the joint posterior distribution, while the light envelopes 234 account also for the uncertainty resulting from of the observed Poisson process.

235

Without intervention, the model predicts that the burden of all-species malaria would have reached a total of 14 053 symptomatic and asymptomatic infections between 2018 and 2020 (Table 2). With the Malakit intervention, this burden is estimated at 7205 new infections overall. We thus estimate that 6848 infections were averted during the two years of the intervention, of which 3218 symptomatic infections. According to our assumptions, we estimate that 970 infections were treated with the use of Malakit.

242

244 Table 2: Cumulated malaria incidence of all-species malaria infections estimated between April

245 2018 and March 2020, with intervention (model fitted to data) and without (counterfactual)

246 (mean and 95%CrI).

	2018-2020 cumulated incidence, all-species malaria infections (95%CrI)			
	No intervention	Intervention	Difference	Variation
Notified (D)	1193 (1101, 1286)	612 (548, 676)	581 (469, 694)	-48.7% (-55.1, -41.7)
Symptomatic, treated by the health system (IT)	1730 (1607, 1852)	887 (803, 971)	843 (694, 991)	-48.7% (-54.5, -42.4)
Symptomatic, treated with a malakit (IM)	-	970 (778, 1163)	-	-
Total symptomatic treated (IT+IM)	1730 (1607, 1852)	1857 (1647, 2067)	-127 (-371, 116)	+7.4% (-6.4, 22.3)
Symptomatic, not treated (IS)	4870 (3771, 5964)	1525 (1103, 1947)	3345 (2166, 4518)	-68.7% (-78.6, -55.4)
Total symptomatic (IT+IM+IS)	6600 (5436, 7761)	3382 (2806, 3959)	3218 (1919, 4514)	-48.7% (-60.0, -34.2)
Asymptomatic, not treated (IA)	7453 (5765, 9138)	3823 (2926, 4717)	3630 (1723, 5537)	-48.7% (-63.3, -28.6)
Total infected (I)	14 053 (12 550, 15 559)	7205 (6408, 8002)	6848 (5147, 8552)	-48.7% (-56.1, -40.2)

247

248 **3.2** Impact on *P. falciparum* and *P. vivax* malaria transmission

When fitted separately to Pf or Pv data, the model estimates a stronger increase in treatment coverage for Pf (from 20.6% to 81.7%) than Pv (from 20.8% to 37.2%) (Table 3). The probability of using Malakit is higher for Pf (61.1%) than Pv (16.4%). This is associated to a sharper decrease of R for Pfthan Pv, 0.96 to 0.34 (-64.2%) vs. 1.13 to 0.95 (-15.9%), respectively.

We find species-specific patterns of malaria transmission: the probability of developing a symptomatic infection (ε) is higher for *Pf* than *Pv*: 77.3% vs. 47.4%. The transmission rate of *Pv* is about four times higher than *Pf* (mean β_0 estimates: 0.037 vs. 0.009 day⁻¹), however the seasonality of transmission is more marked for *Pf* than *Pv*, with seasonal amplitudes of transmission rate (α) estimated at 0.17 °C⁻¹

257 vs. 0.08 $^{\circ}$ C⁻¹, respectively.

- 258
- 259
- 260
- 261
- 262

263 Table 3: Posterior distributions (mean and 95% credible interval) for *P. falciparum* and *P. vivax*

264 malaria transmission models.

Parameter	Period	P. falciparum	P. vivax	
a. Tuestment serverses	Pre-intervention	20.6% (17.0, 25.7)	20.8% (18.0, 23.9)	
φ: Treatment coverage	Intervention	81.7% (67.9, 96.4)	37.2% (33.6, 41.1)	
m: Malakit agyaraga*	Pre-intervention	-	-	
m: Malakit coverage*	Intervention	61.1% (47.9, 74.0)	16.4% (13.8, 19.1)	
a Drohability of ground and	Pre-intervention	77 20/ (56 1 07 2)	47.4% (37.9, 59.0)	
ε: Probability of symptoms	Intervention	77.3% (56.1, 97.3)		
β_0 : Transmission rate at average	Pre-intervention	0.000 (0.007, 0.010)	0.037 (0.030, 0.045)	
temperature (day ⁻¹)	Intervention	0.009 (0.007, 0.010)		
α: Seasonal amplitude of	Pre-intervention	0.174 (0.138, 0.211)	0.075 (0.057, 0.093)	
transmission rate (°C ⁻¹)	Intervention	0.174 (0.138, 0.211)		
lag: Temperature lag of	Pre-intervention	78 (66, 89)	82 (69, 07)	
transmission rate (days)	Intervention	78 (00, 89)	82 (68, 97)	
T: Mean infection duration (all	Pre-intervention	112 [91, 131]	31 [25, 37]	
infections)*	Intervention	40 [26, 56]	26 [21, 31]	
R: Mean reproduction number (all	Pre-intervention	0.96 [0.93, 1.00]	1.13 [1.11, 1.15]	
infections)*	Intervention	0.34 [0.22, 0.46]	0.95 [0.92, 0.98]	

* Calculated from other parameters (see supplementary methods)

265

When comparing intervention to counterfactual estimates, the estimated impact of Malakit on incidence rate is stronger for Pf (-63.1%) than Pv (-42.8%) (supplementary Table 6). However, the estimated contribution of Malakit to the total variation of the incidence rate since the beginning of the intervention is more modest for Pf (52.0%) than Pv (88.6%). A similar pattern is observed with the total prevalence for both species. These findings reflect the stronger decrease of Pf infection incidence and prevalence compared to Pv for reasons other than Malakit, in line with a mean reproduction number estimated lower than one before intervention for Pf, but not for Pv.

273 We estimate that 713 (95% CrI 507, 920) new *Pf* and 3686 (95% CrI 3067, 4303) new *Pv* symptomatic 274 infections occurred during the intervention period (Table 4). Without intervention, the counterfactual 275 scenario predicts that this burden would have reached 1944 (95% CrI 1336, 2550) Pf and 6452 (95% CrI 276 5311, 7591) Pv infections. We thus estimate that between 2018 and 2020 Malakit helped avert a total 277 of 1231 NSI of *Pf* (95% CrI 589, 1870) and 2766 NSI of *Pv* (95% CrI 1471, 4063). The model estimates 278 that 432 (95%CrI 311, 554) Pf and 605 (95%CrI 468, 742) Pv infections were treated by a malakit 279 during the intervention. In line with a stronger increase of treatment coverage for Pf than Pv, we find 280 a larger decrease of the incidence of symptomatic infections not treated (or incompletely) for Pf (-281 91.3%) than Pv (-54.6%).

282 Table 4: Cumulated malaria incidence of *P. falciparum* and *P. vivax* malaria infections estimated

283 between April 2018 and March 2020, with intervention (model fitted to data) and without

284 (counterfactual)

	Scenario	<i>P. falciparum</i> infections (95%CrI)	<i>P. vivax</i> infections (95%CrI)
Notified to surveillance	No intervention	272 (220, 323)	917 (835, 999)
(D)	Intervention	100 (76, 125)	524 (465, 583)
	Difference	172 (115, 229)	393 (292, 494)
	Variation	-63.1% (-73.5, -50.1)	-42.8% (-50.7, -34.1)
Symptomatic, treated by the	No intervention	394 (324, 464)	1329 (1221, 1438)
health system	Intervention	145 (113, 177)	760 (682, 838)
(IT)	Difference	249 (172, 326)	569 (436, 703)
	Variation	-63.1% (-72.6, -51.4)	-42.8% (-50.0, -34.9)
Symptomatic, treated with a	No intervention	-	-
malakit	Intervention	432 (311, 554)	605 (468, 742)
(IM)	Difference	-	-
	Variation	-	-
Total symptomatic treated	No intervention	394 (324, 464)	1329 (1221, 1438)
(IT+IM)	Intervention	577 (449, 705)	1365 (1211, 1518)
	Difference	-183 (-329, -38)	-36 (-223, 153)
	Variation	+46.3% (8.7, 93.9)	+2.6% (-11.0, 17.7)
Symptomatic, not treated	No intervention	1550 (991, 2106)	5123 (4040, 6201)
(IS)	Intervention	136 (0, 274)	2321 (1816, 2826)
	Difference	1414 (838, 1987)	2802 (1606, 3993)
	Variation	-91.3% (-100.1, -79.7)	-54.6% (-66.8, -38.3)
Total symptomatic	No intervention	1944 (1336, 2550)	6452 (5311, 7591)
(IT+IM+IS)	Intervention	713 (507, 920)	3686 (3067, 4303)
	Difference	1231 (589, 1870)	2766 (1471, 4063)
	Variation	-63.1% (-76.3, -42.4)	-42.8% (-55.3, -26.8)
Asymptomatic, not treated	No intervention	578 (11, 1145)	7176 (5213, 9137)
(IA)	Intervention	214 (0, 427)	4104 (2921, 5284)
	Difference	364 (-241, 971)	3072 (784, 5359)
	Variation	-63.1% (-119.4, 136.2)	-42.8% (-62.2, -14.2)
Total infected	No intervention	2522 (1968, 3077)	13 628 (11937, 15324)
(I)	Intervention	927 (734, 1120)	7790 (6739, 8840)
	Difference	1595 (1009, 2183)	5838 (3850, 7834)
	Variation	-63.1% (-72.9, -49.9)	-42.8% (-52.6, -31.4)

285

286

288 **4 Discussion**

289 We have here presented a mathematical model, coupled with Bayesian inference, to jointly analyze 290 three independent datasets: surveillance data from Brazil, from Suriname, and prevalence data from repeated cross-sectional surveys. We find an increase of treatment coverage from 26.4% to 55.1% with 291 292 the implementation of the Malakit intervention, which resulted in a strong decrease of malaria 293 transmission, and a drop of the estimated reproduction number from 1.19 to 0.86 for all-species 294 malaria. Indeed, access to prompt treatment by ACT and S-PQ (both medication included in Malakit) 295 accelerate the clearance of circulating gametocytes, and thus decrease the duration of the infection for 296 one episode of Pf or Pv malaria (18). Because Malakit does not offer a radical cure against Pv 297 hypnozoites, subsequent Pv relapses cannot be prevented. This can explain the lower impact of Malakit 298 estimated on Pv transmission, as reported when ACT was implemented in other settings (19). Malakit 299 could also have had an effect on malaria transmission through the increased use of long lasting 300 insecticidal nets (LLINs), by improving access and awareness of this preventive measure among 301 participants (20). However, there is little evidence about the effectiveness of LLINs for malaria 302 prevention in this context given one fifth of gold miners report working at night and the diurnal biting 303 behavior of An. darlingi observed in the Guianese rainforest (21,22).

304 To our knowledge, Malakit was the only intervention implemented at full scale between 2018 and 2020 305 in the gold mining population, and no significant changes occurred in the management of the health 306 systems of French Guiana, Suriname and Brazil during that period for this population. Our model 307 accounts for seasonal and long-term climate variations with a force of transmission dependent on 308 temperature, and weather records show that temperature and rainfall were quite stable between 2014 309 and 2020 in French Guiana. Gold mining activity appears to have remained stable over this period. 310 Police operations implemented since 2008 by the French authorities aim to destroy logistical equipment 311 and mining networks, but they are struggling to reduce the number of gold miners. A stable number of 312 police operations were conducted between 2015 and 2019, with the exception of March-April 2017 313 (23).

- We find that, after two years of intervention, Malakit contributed to halving the incidence of malaria infection from 340 to 184 NSI/1000/year. Those estimates are similar to findings from pre-post field surveys: 306 to 142 NSI/1000/year (supplementary material). The field surveys also indicate a similar 2.4-fold increase of treatment coverage (vs. 2.1 with our model), but with a larger post-intervention estimate: 27.3% before intervention and 66.2% after intervention (supplementary Table 3), compared with 26.4% and 55.1%, respectively, found here.
- Our results suggest that a significant progression towards malaria elimination was achieved in our study population during the implementation of Malakit, with estimated values of R below unity, the theoretical threshold for malaria elimination (24). We find that the elimination process of *Pf* preceded the intervention (R=0.96) and accelerated during its implementation (R=0.34). This is mirrored by the
- evolution of the incidence rate of *Pf* infection, compatible with a shift from a low transmission intensity
- 325 (> 100 cases/1000/year) to a very low transmission intensity (< 100 cases/1000/year) (25). In contrast,
- 326 for *Pv*, the shift of R below the elimination threshold was concomitant with the intervention.

327 According to WHO's framework, the stratification of malaria risk is an important step for planning and 328 achieving malaria elimination (25). This relies on epidemiological and ecological assessments, which 329 is particularly challenging in the case of our population given their high mobility and the difficulties to reach clandestine gold mining areas. We modeled malaria transmission on a single patch with the 330 assumption of homogeneous transmission in all mining sites, our results thus reflect an averaged 331 332 picture of a more complex and heterogeneous reality. The progressive reduction of malaria incidence 333 will increase this spatial and temporal heterogeneity, making it even more challenging to evaluate 334 future interventions. Along with immunity loss and mobility, this should be taken into consideration

in future works, for example in a stochastic or agent-based model (26).

336 Generating robust evidence about the effectiveness and impact of public health intervention is difficult, especially when working with mobile and hard-to-reach populations. Clustered randomized trials, 337 338 commonly held as the gold standard design for outcome evaluation, are impractical to implement in 339 this context (27). As an illustration, we only identified two published trials which evaluated a malaria 340 control intervention amongst a hard-to-reach population in the past ten years (28,29). The model 341 proposed here optimally combines different sources of data, each providing partial information, and its 342 findings are in line with those estimated independently from pre-post intervention field surveys. This model-based triangulation approach can be used in similar situations to better inform decision-making 343 344 towards malaria elimination in especially challenging environments.

345

346 **5** Conclusion

347 Through a modeling approach, we assess the effectiveness of Malakit as a malaria control intervention 348 in the specific context of the mobile and hard-to-reach population involved in illegal gold mining in 349 French Guiana. Our findings show that Malakit had a significant impact on both *P. falciparum* and *P.* 350 vivax transmission, through an improved access to prompt treatment by ACT and S-PQ for the 351 treatment of symptomatic malaria infections. Building on the efforts of the healthcare community 352 during the past twenty years, Malakit constitutes an additional step towards malaria elimination in the 353 Guiana Shield. This new intervention – training individuals to self-diagnose and self-treat using a free 354 kit - could integrate strategies aiming at eliminating malaria in populations beyond the reach of the 355 health systems.

356

358 **Contributors**

- 359 MD, MG, YL, MSM, SV, HH, PM and AS conceived Malakit study and wrote the protocol.
- 360 YL, AS, MD, HH and PM accessed and verified the data.
- 361 YL, CP, RM developed the model.
- 362 YL coded and calibrated the model, analyzed the data and results.
- 363 YL, MD, RM and CP wrote the draft of the manuscript.
- 364 All authors reviewed the manuscript.
- 365

366 **Declaration of interests**

- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- 369

370 Funding

- 371 Cayenne Hospital, as sponsor, directly managed most of the project funds. Half of the funding was by
- the European Regional Development Fund via the Interregional Amazon Cooperation Program 2014-
- 373 2020, supplemented with self-funding from Cayenne Hospital, funds from the French Guiana Health
- 374 Regional Agency, the European Horizon 2020 Program and contributions in kind from the Suriname
- 375 National Malaria Program, as beneficiary of the Global Fund to Fight AIDS, Tuberculosis and Malaria;
- the Ministry of Health of Brazil; and the French Development Agency.
- 377 The funding bodies played no part in the implementation and evaluation of the project.

378

379 Data sharing

380 Monthly aggregated surveillance data, R scripts and MCMC traces are available upon request to the 381 corresponding author (YL).

382

383 Abbreviations

- 384 ACT: Artemisinin combined therapy
- 385 ITSA: Interrupted time series analysis
- 386 LLIN: Long lasting insecticidal net

- 387 NSI: New symptomatic infection
- 388 NSI/1000/year: New symptomatic infections per 1000 individuals
- 389 PCR: Polymerase chain reaction
- 390 *Pf: Plasmodium falciparum*
- 391 Pv: Plasmodium vivax
- 392 RDT: Rapid diagnostic test
- 393 S-PQ: Single-dose primaquine
- 394

395 Acknowledgments

396 We thank all the facilitators of the Malakit project who contributed to the successful implementation

397 of the intervention, Dr Lise Musset and Dr Yassamine Lazrek from the Institut Pasteur de la Guyane,

398 for PCR prevalence data, and the Ministries of Health of Suriname and Brazil for the sharing of

399 surveillance data.

400 OML is a staff member of the Pan American Health Organization / World Health Organization

- 401 (PAHO/WHO). The author alone is responsible for the views expressed in this publication and do not
- 402 necessarily represent the decisions, policy or views of the PAHO / WHO

404 **References**

- Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing
 epidemiology of malaria elimination: new strategies for new challenges. The Lancet. 7 sept
 2013;382(9895):900-11.
- 408
 408
 409
 409 and migrant population in Cambodia: a population movement framework to inform strategies for
 410 malaria control and elimination. Malar J. 20 juin 2015;14:252.
- 411 3. Wangdi K, Pasaribu AP, Clements ACA. Addressing hard-to-reach populations for achieving 412 malaria elimination in the Asia Pacific Malaria Elimination Network countries. Asia Pac Policy 413 Stud [Internet]. 2021 [cité 2021];n/a(n/a). Disponible 25 mars sur: 414 https://onlinelibrary.wiley.com/doi/abs/10.1002/app5.315
- 4. Douine M, Lambert Y, Musset L, Hiwat H, Blume LR, Marchesini P, et al. Malaria in Gold Miners
 in the Guianas and the Amazon: Current Knowledge and Challenges. Curr Trop Med Rep
 [Internet]. 21 mars 2020 [cité 4 juin 2020]; Disponible sur: https://doi.org/10.1007/s40475-02000202-5
- 419 5. Douine M, Musset L, Corlin F, Pelleau S, Pasquier J, Mutricy L, et al. Prevalence of Plasmodium 420 spp. in illegal gold miners in French Guiana in 2015: a hidden but critical malaria reservoir. Malar 421 [Internet]. 2019];15. Disponible J 9 juin 2016 [cité 3 oct sur: 422 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899929/
- 423 6. Hiwat H, Martínez-López B, Cairo H, Hardjopawiro L, Boerleider A, Duarte EC, et al. Malaria
 424 epidemiology in Suriname from 2000 to 2016: trends, opportunities and challenges for elimination.
 425 Malar J. 2018;17(1):418.
- 426 7. Douine M, Sanna A, Galindo M, Musset L, Pommier de Santi V, Marchesini P, et al. Malakit: an
 427 innovative pilot project to self-diagnose and self-treat malaria among illegal gold miners in the
 428 Guiana Shield. Malar J [Internet]. 10 avr 2018 [cité 3 oct 2019];17. Disponible sur:
 429 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892004/
- 8. Douine M, Lambert Y, Galindo MS, Mutricy L, Sanna A, Peterka C, et al. Self-diagnosis and self-treatment of malaria in hard-to-reach and mobile populations of the Amazon: results of Malakit, an international multicentric intervention research project. Lancet Reg Health Am. 1 déc 2021;4:100047.
- 434 9. Heemskerk M, Eelco Jacobs, Pierre Pratley. Technical Report Mobile Migrant population study
 435 Suriname. KIT; 2021.
- 436 10. Galindo MS, Lambert Y, Mutricy L, Garancher L, Bordalo Miller J, Gomes JH, et al. Setting-up a
 437 cross-border action-research project to control malaria in remote areas of the Amazon: describing

- the birth and milestones of a complex international project (Malakit). Malar J. 11 mai
 2021;20(1):216.
- Lambert Y, Galindo M, Suárez-Mutis M, Mutricy L, Sanna A, Garancher L, et al. Tailoring Mobile
 Data Collection for Intervention Research in a Challenging Context: Development and
 Implementation in the Malakit Study. JMIR Form Res. 16 juin 2022;6(6):e29856.
- 443 12. Koella J, Antia R. Epidemiological models for the spread of anti-malarial resistance. Malar J. 19
 444 févr 2003;2:3.
- 445 13. Smith DL, Ellis McKenzie F. Statics and dynamics of malaria infection in Anopheles mosquitoes.
 446 Malar J. 4 juin 2004;3(1):13.
- 447 14. Dudley HJ, Goenka A, Orellana CJ, Martonosi SE. Multi-year optimization of malaria
 448 intervention: a mathematical model. Malar J [Internet]. 1 mars 2016 [cité 9 sept 2018];15.
 449 Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774123/
- 450 15. Vihola M. Robust adaptive Metropolis algorithm with coerced acceptance rate. Stat Comput. 1 sept
 451 2012;22(5):997-1008.
- 452 16. Helske J. ramcmc: Building blocks for Robust Adaptive Metropolis algorithm [Internet]. Finland:
 453 University of Jyväskylä; 2016 [cité 15 oct 2022]. Disponible sur: https://cran.r454 project.org/web/packages/ramcmc/vignettes/ramcmc.html#ref-Vihola2012
- 455 17. Plummer M, Best N, Cowles K, Vines K, Sarkar D, Bates D, et al. coda: Output Analysis and
 456 Diagnostics for MCMC [Internet]. 2020 [cité 15 oct 2022]. Disponible sur: https://CRAN.R457 project.org/package=coda
- 458 18. Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ. Reduction of transmission from
 459 malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials.
 460 Malar J. 9 juill 2008;7(1):125.
- 461 19. Kenangalem E, Poespoprodjo JR, Douglas NM, Burdam FH, Gdeumana K, Chalfein F, et al.
 462 Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based
 463 treatment for malaria in Papua, Indonesia: A longitudinal surveillance study. PLOS Med. 29 mai
 464 2019;16(5):e1002815.
- 465 20. Longchamps C, Galindo M, Lambert Y, Sanna A, Mutricy L, Garancher L, et al. Impact of Malakit 466 intervention on perceptions, knowledge, attitudes, and practices related to malaria among workers in clandestine gold mines in French Guiana: results of multicentric cross-sectional surveys over 467 time [Internet]. 468 2022 [cité 31 mars 2022]. Disponible sur: 469 https://www.researchsquare.com/article/rs-1362837/v1

- 21. Douine M, Mosnier E, Le Hingrat Q, Charpentier C, Corlin F, Hureau L, et al. Illegal gold miners
 in French Guiana: a neglected population with poor health. BMC Public Health. 17 juill
 2017;18(1):23.
- 473 22. Pommier de Santi V, Dusfour I, de Parseval E, Lespinet B, Nguyen C, Gaborit P, et al. Risk of
 474 daytime transmission of malaria in the French Guiana rain forest. Med Sante Trop. 1 févr
 475 2017;27(1):111-2.
- 476 23. Le Tourneau FM. Chercheurs d'or: l'orpaillage clandestin en Guyane française. Paris: CNRS;
 477 2020. 421 p.
- 478 24. Griffin JT. Is a reproduction number of one a threshold for Plasmodium falciparum malaria
 479 elimination? Malar J. 26 juill 2016;15(1):389.
- 480 25. World Health Organization. A framework for malaria elimination [Internet]. Geneva: World
 481 Health Organization; 2017 [cité 1 mai 2022]. Disponible sur:
 482 https://apps.who.int/iris/handle/10665/254761
- 26. Smith NR, Trauer JM, Gambhir M, Richards JS, Maude RJ, Keith JM, et al. Agent-based models
 of malaria transmission: a systematic review. Malar J [Internet]. 17 août 2018 [cité 9 déc 2018];17.
 Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098619/
- 486 27. Sanson-Fisher RW, Bonevski B, Green LW, D'Este C. Limitations of the Randomized Controlled
 487 Trial in Evaluating Population-Based Health Interventions. Am J Prev Med. 1 août
 488 2007;33(2):155-61.
- 28. Tripura R., von Seidlein L., Sovannaroth S., Peto T.J., Callery J.J., Sokha M., et al. Antimalarial
 chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised
 controlled trial. Lancet Infect Dis. 2023;23:81-90.
- 492 29. Bennett A., Dantzer E., Hongvanthong B., Rerolle F., Hocini S., Smith J., et al. Targeted
 493 surveillance for forest-based malaria transmission: Results of a cluster randomized controlled trial
 494 in southern Lao PDR. Am J Trop Med Hyg. 2019;101(5 Supplement):216.
- 495